Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Depreciation and Depletion: 2019-2025

Historic Depreciation and Depletion for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to $5.6 million.

  • Beam Therapeutics' Depreciation and Depletion rose 1.55% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.1 million, marking a year-over-year increase of 1.03%. This contributed to the annual value of $21.9 million for FY2024, which is 9.56% up from last year.
  • Per Beam Therapeutics' latest filing, its Depreciation and Depletion stood at $5.6 million for Q3 2025, which was up 0.40% from $5.5 million recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Depreciation and Depletion peaked at $5.6 million during Q2 2024, and registered a low of $1.4 million during Q1 2021.
  • In the last 3 years, Beam Therapeutics' Depreciation and Depletion had a median value of $5.4 million in 2024 and averaged $5.3 million.
  • Per our database at Business Quant, Beam Therapeutics' Depreciation and Depletion surged by 133.33% in 2022 and then dropped by 0.68% in 2025.
  • Beam Therapeutics' Depreciation and Depletion (Quarterly) stood at $2.6 million in 2021, then spiked by 54.12% to $3.9 million in 2022, then surged by 35.95% to $5.4 million in 2023, then grew by 1.51% to $5.4 million in 2024, then rose by 1.55% to $5.6 million in 2025.
  • Its last three reported values are $5.6 million in Q3 2025, $5.5 million for Q2 2025, and $5.5 million during Q1 2025.